Targeting nuclear receptor-binding SET domain protein 2 (NSD2) for cancer therapy: Challenges and emerging strategies

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Nuclear receptor-binding SET domain protein 2 (NSD2) is implicated in the pathogenesis and progression of various cancers.
• NSD2 is recognized as a promising therapeutic target for tumor-related diseases.
• NSD2 inhibitors and degraders are emerging as critical research areas in oncology drug development.

Purpose of the Study:

• To systematically review and analyze existing NSD2 inhibitors and degraders for tumor therapy.
• To classify these small molecules based on structural characteristics.
• To provide insights for developing safer, more effective, and targeted NSD2-based therapeutics.

Main Methods:

• Literature review and systematic analysis of NSD2 inhibitors and degraders.
• Classification of small molecules by structural features.
• Detailed examination of binding modes, structural characteristics, and pharmacological activities.
• Critical evaluation of the advantages and limitations of identified compounds.

Main Results:

• Several NSD2 inhibitors and degraders have been identified, though most are in early development.
• Compounds were analyzed based on structural categories, revealing diverse binding modes and activities.
• Key advantages and limitations of different structural classes were critically assessed.

Conclusions:

• The review provides a comprehensive overview of NSD2 small-molecule agents for cancer therapy.
• Insights gained can guide the future development of improved NSD2 inhibitors and degraders.
• Further research is needed to advance these agents towards clinical application.